What's Happening?
Verastem Oncology has announced two-year median follow-up data from its Phase 2 RAMP 201 clinical trial, which evaluated the AVMAPKI® FAKZYNJA® combination therapy in patients with recurrent low-grade serous ovarian cancer (LGSOC). The data was presented
at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting. The trial demonstrated sustained clinical benefits, with 52% of patients with a KRAS mutation and 30% of patients with KRAS wild-type remaining on therapy for over a year. The combination therapy showed a well-tolerated safety profile with no new safety signals and a low discontinuation rate due to adverse events. The study highlights the durability of response and suggests that patients can benefit from long-term administration of the therapy.
Why It's Important?
The findings from this study are significant as they provide evidence of a durable and clinically meaningful treatment option for patients with recurrent LGSOC, a condition with limited treatment options. The therapy's ability to maintain efficacy over a prolonged period could improve the quality of life for patients, particularly those with KRAS mutations, who represent a substantial portion of the LGSOC population. The data also underscores the manageable safety profile of the combination therapy, which could distinguish it from previous MEK-based treatments. This development could influence treatment protocols and offer hope to patients with this rare form of ovarian cancer.
What's Next?
Verastem is conducting further studies, including the RAMP 301 Phase 3 confirmatory trial, to evaluate the combination therapy against standard chemotherapy or hormonal therapy for recurrent LGSOC. The company is also exploring the use of the therapy in combination with standard chemotherapy for advanced pancreatic cancer. These ongoing trials will be crucial in confirming the clinical benefits observed and could potentially lead to broader regulatory approvals and adoption in clinical practice.
